Abstract:Objective The aim of this study was to evaluate the cost-effectiveness of liraglutide 1.2mg once daily versus other commonly used anti-diabetic drugs in patients with type 2 diabetes (T2DM)achieving a composite endpoint of HbA1c<7.0%,no weight gain,and no hypoglycaemia at week 26.Methods The study compared anti-diabetic drugs with clinical evidence in the〝Liraglutide Effect and Action in Diabetes(LEADTM)〞clinical trial program,including rosiglitazone,glimepiride,exenatide and insulin glargine.Results were calculated as cost per patient successful y treated to the target composite end point.Effectiveness data of patients achieving the composite endpoint of HbA1c<7.0%,no weight gain,and no hypoglycaemia at week 26 were derived from a meta-analysis.Medical costs included the cost of drugs, needles,self-monitoring of blood glucose(SMBG) strips,hypoglycaemia,weight loss and serious adverse events.One way sensitivity analysis was performed.Results Within 26 weeks,comparing with rosiglitazone,glimepiride, exenatide and insulin glargine,liraglutide 1.2mg made 26,24,7 and 17 additional patients achieve the composite end point every 100 patients respectively.The cost per patient successful y treated with liraglutide to the target composite end point is lower than al the other comparators.Sensitivity analyses demonstrated robustness of the results.Conclusion The analysis demonstrates that liraglutide was a cost-effective approach Cascompared with rosiglitazone,glimepiride,exenatide and insulin glargine.

Short-term Cost-effectiveness of Liraglutide Versus Rosiglitazone、Glimepiride、Exenatide and Insulin Glargine in Chinese Patients with type 2 Diabetes